3
IRUS Total
Downloads

Infliximab and tofacitinib attenuate neutralizing antibody responses against SARS-CoV-2 ancestral and Omicron variants in IBD patients following 3 doses of COVID-19 vaccine

File Description SizeFormat 
1-s2.0-S0016508522011842-main.pdfPublished version352.76 kBAdobe PDFView/Open
Title: Infliximab and tofacitinib attenuate neutralizing antibody responses against SARS-CoV-2 ancestral and Omicron variants in IBD patients following 3 doses of COVID-19 vaccine
Authors: Liu, Z
Alexander, J
LIN, K
Pollock, K
Powell, N
Item Type: Journal Article
Issue Date: Feb-2023
Date of Acceptance: 12-Oct-2022
URI: http://hdl.handle.net/10044/1/100121
DOI: 10.1053/j.gastro.2022.10.010
ISSN: 0016-5085
Publisher: Elsevier
Start Page: 300
End Page: 303.e3
Journal / Book Title: Gastroenterology
Volume: 164
Issue: 2
Copyright Statement: © 2023 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Publication Status: Published
Online Publication Date: 2022-10-19
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Department of Surgery and Cancer
Department of Infectious Diseases
Faculty of Medicine
Imperial College London COVID-19



This item is licensed under a Creative Commons License Creative Commons